DeepMed Research

Akeso

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $5B

Website

Clinical Trials

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: AK117
Drug: Azacitidine

First Posted Date: 2021-07-28

Last Posted Date: 2025-03-03

Lead Sponsor: Akeso

Target Recruit Count: 68

Registration Number: NCT04980885

Locations: 🇨🇳
The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3

Active, not recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Penpulimab
Drug: placebo

First Posted Date: 2021-07-23

Last Posted Date: 2025-04-13

Lead Sponsor: Akeso

Target Recruit Count: 296

Registration Number: NCT04974398

Locations: 🇧🇷
Grupo Oncoclínicas, Botafogo, Reg1, Brazil
🇧🇷
Hospital Bruno Born, Lajeado, Reg1, Brazil
🇺🇸
City of Hope, Duarte, California, United States

and more 53 locations

A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

Phase 1

Active, not recruiting

Conditions: Myelodysplastic Syndrome

Interventions: Drug: AK117
Drug: Azacitidine

First Posted Date: 2021-05-25

Last Posted Date: 2025-03-03

Lead Sponsor: Akeso

Target Recruit Count: 136

Registration Number: NCT04900350

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

Phase 1

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: AK112

First Posted Date: 2021-05-25

Last Posted Date: 2025-03-03

Lead Sponsor: Akeso

Target Recruit Count: 108

Registration Number: NCT04900363

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Phase 2

Completed

Conditions: Recurrent or Metastatic Cervical Cancer

Interventions: Biological: AK104
Biological: Bevacizumab
Drug: Paclitaxel
Drug: Cisplatin or Carboplatin

First Posted Date: 2021-05-03

Last Posted Date: 2025-03-04

Lead Sponsor: Akeso

Target Recruit Count: 50

Registration Number: NCT04868708

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Study of AK112 in the Treatment of Advanced Gynecological Tumors

Phase 2

Completed

Conditions: Ovarian Neoplasms
Gynecologic Cancer
Endometrial Neoplasms
Cancer Metastatic
Cervical Neoplasm

Interventions: Drug: AK112

First Posted Date: 2021-05-03

Last Posted Date: 2025-02-28

Lead Sponsor: Akeso

Target Recruit Count: 53

Registration Number: NCT04870177

Locations: 🇨🇳
Chongqing University Cancer Hospital, Chongqing, China
🇨🇳
Qilu Hospital of Shandong University, Qilu, Shandong, China

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Biological: AK105
Drug: Cisplatin
Drug: Gemcitabine
Drug: Anlotinib hydrochloride

First Posted Date: 2021-02-03

Last Posted Date: 2025-03-07

Lead Sponsor: Akeso

Target Recruit Count: 28

Registration Number: NCT04736810

Locations: 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

Phase 2

Recruiting

Conditions: NSCLC

Interventions: Drug: AK112
Drug: Pemetrexed
Drug: Docetaxel
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2021-02-03

Last Posted Date: 2025-03-07

Lead Sponsor: Akeso

Target Recruit Count: 296

Registration Number: NCT04736823

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guanzhou, Guangdong, China

A Phase 1 Dose Escalation and Expansion Study of AK117

Phase 1

Completed

Conditions: Neoplasms Malignant

Interventions: Drug: AK117

First Posted Date: 2021-01-28

Last Posted Date: 2025-03-03

Lead Sponsor: Akeso

Target Recruit Count: 49

Registration Number: NCT04728334

Locations: 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Biological: AK104
Biological: AK104 lenvatinib

First Posted Date: 2021-01-28

Last Posted Date: 2024-04-25

Lead Sponsor: Akeso

Target Recruit Count: 32

Registration Number: NCT04728321

Locations: 🇨🇳
The first affilited hospital zhejiang university school of medcine, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy